Divergent control of Cav-1 expression in non-cancerous Li-Fraumeni syndrome and human cancer cell lines.

Abstract:

:Li-Fraumeni syndrome (LFS) is primarily characterized by development of tumors exhibiting germ-line mutations in the p53 gene. Cell lines developed from patients of a LFS family have decreased p53 activity as evidenced by the absence of apoptosis upon etoposide treatment. To test our hypothesis that changes in gene expression beyond p53 per se are contributing to the development of tumors, we compared gene expression in non-cancerous skin fibroblasts of LFS-affected (p53 heterozygous) vs. non-affected (p53 wild-type homozygous) family members. Expression analysis showed that several genes were differentially regulated in the p53 homozygous and heterozygous cell lines. We were particularly intrigued by the decreased expression (~88%) of a putative tumor-suppressor protein, caveolin-1 (Cav-1), in the p53-mutant cells. Decreased expression of Cav-1 was also seen in both p53-knockout and p21-knockout HTC116 cells suggesting that p53 controls Cav-1 expression through p21 and leading to the speculation that p53, Cav-1 and p21 may be part of a positive auto-regulatory feedback loop. The direct relationship between p53 and Cav-1 was also tested with HeLa cells (containing inactive p53), which expressed a significantly lower Cav-1 protein. A panel of nonfunctional and p53-deficient colon and epithelial breast cancer cell lines showed undetectable expression of Cav-1 supporting the role of p53 in the control of Cav-1. However, in two aggressively metastasizing breast cancer cell lines, Cav-1 was strongly expressed suggesting a possible role in tumor metastasis. Thus, there is a divergent control of Cav-1 expression as evidenced in non-cancerous Li-Fraumeni syndrome and some aggressive human cancer cell lines.

journal_name

Cancer Biol Ther

journal_title

Cancer biology & therapy

authors

Sherif ZA,Sultan AS

doi

10.4161/cbt.22621

subject

Has Abstract

pub_date

2013-01-01 00:00:00

pages

29-38

issue

1

eissn

1538-4047

issn

1555-8576

pii

22621

journal_volume

14

pub_type

杂志文章
  • Hes1: a key role in stemness, metastasis and multidrug resistance.

    abstract::Hes1 is one mammalian counterpart of the Hairy and Enhancer of split proteins that play a critical role in many physiological processes including cellular differentiation, cell cycle arrest, apoptosis and self-renewal ability. Recent studies have shown that Hes1 functions in the maintenance of cancer stem cells (CSCs)...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.1080/15384047.2015.1016662

    authors: Liu ZH,Dai XM,Du B

    更新日期:2015-01-01 00:00:00

  • Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.

    abstract::Objective: Chimeric antigen receptor T (CAR-T) cell therapy has demonstrated an unprecedented therapeutic efficacy in hematological malignancies; however, its effectiveness in solid tumors remains elusive. In order to enable CAR-T cells more effective to solid tumors, a inverted chimeric cytokine receptor (ICR) was de...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2020.1739952

    authors: Weimin S,Abula A,Qianghong D,Wenguang W

    更新日期:2020-06-02 00:00:00

  • Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma.

    abstract::Polo-like kinase 1 (Plk1) is a key cell cycle regulator that is frequently overexpressed in human hepatocellular carcinomas. Blockade of the Plk1 pathway has been reported to be capable of inducing anti-tumor effect. Here, plasmids containing U6 promoter-driven shRNAs against human Plk1 were constructed and transfecte...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.11.4.14178

    authors: Deng H,Jiang Q,Yang Y,Zhang S,Ma Y,Xie G,Chen X,Qian Z,Wen Y,Li J,Yang J,Chen L,Zhao X,Wei Y

    更新日期:2011-02-15 00:00:00

  • CXCL4 mediates tumor regrowth after chemotherapy by suppression of antitumor immunity.

    abstract::The recurrence of colorectal cancer after chemotherapy is the leading cause of its high mortality. We propose that elucidating the mechanisms of tumor regrowth after chemotherapy in tumor-bearing mice may provide new insights into tumor relapse in cancer patients. We firstly report the identification of a chemokine, C...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1095404

    authors: Zhang Y,Gao J,Wang X,Deng S,Ye H,Guan W,Wu M,Zhu S,Yu Y,Han W

    更新日期:2015-01-01 00:00:00

  • In vivo long-term imaging and radioiodine therapy by sodium-iodide symporter gene expression using a lentiviral system containing ubiquitin C promoter.

    abstract::To establish stable and long-term gene expression in vitro and in vivo, we developed a lentiviral vector system carrying sodium iodide symporter (hNIS) gene under UbC promoter, and transfected this into a colon cancer cell line. The in vitro and in vivo kinetics of radioiodine and [99mTc]-pertechnetate were then inves...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.7.4342

    authors: Kim HJ,Jeon YH,Kang JH,Lee YJ,Kim KI,Chung HK,Jeong JM,Lee DS,Lee MC,Chung JK

    更新日期:2007-07-01 00:00:00

  • Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo.

    abstract::Cancer cells convert glucose preferentially to lactate even in the presence of oxygen (aerobic glycolysis-Warburg effect). New concepts in cancer treatment aim at inhibition of aerobic glycolysis. Pyruvate dehydrogenase converts pyruvate to acetylCoA thus preventing lactate formation. Therefore, the aim of this study ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.22003

    authors: Feuerecker B,Pirsig S,Seidl C,Aichler M,Feuchtinger A,Bruchelt G,Senekowitsch-Schmidtke R

    更新日期:2012-12-01 00:00:00

  • Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model.

    abstract:OBJECTIVES:The key objective of the study was to determine the single and multiple dose toxicity and efficacy of Bismuth-213 labeled PAI2 based targeted alpha therapy by selectively targeting uPA and uPAR in regressing prostate cancer in a nude mouse model. Targeted alpha therapy (TAT) is an experimental therapeutic mo...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.5.4.2478

    authors: Abbas Rizvi SM,Li Y,Song EY,Qu CF,Raja C,Morgenstern A,Apostolidis C,Allen BJ

    更新日期:2006-04-01 00:00:00

  • Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.

    abstract::We report 3 cases of durable complete response (CR) in patients with BRAF-mutated metastatic melanoma who were initially treated unsuccessfully with sequential immunotherapies (high dose interleukin 2 followed by ipilimumab with or without concurrent radiation therapy). After progression during or post immunotherapy, ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1026507

    authors: Wyluda EJ,Cheng J,Schell TD,Haley JS,Mallon C,Neves RI,Robertson G,Sivik J,Mackley H,Talamo G,Drabick JJ

    更新日期:2015-01-01 00:00:00

  • c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells.

    abstract::The novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) induces apoptosis of cancer cells, enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, and exhibits potent anticancer activity in animal models with a favorable pharmacokinetic profile....

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.10.4763

    authors: Zou W,Chen S,Liu X,Yue P,Sporn MB,Khuri FR,Sun SY

    更新日期:2007-10-01 00:00:00

  • The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.

    abstract::Rhabdomyosarcoma (RMS) is an aggressive childhood sarcoma with two distinct subtypes, embryonal (ERMS) and alveolar (ARMS) histologies. More effective treatment is needed to improve outcomes, beyond conventional cytotoxic chemotherapy. The pan-histone deacetylase inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), has ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2018.1529093

    authors: Ghayad SE,Rammal G,Sarkis O,Basma H,Ghamloush F,Fahs A,Karam M,Harajli M,Rabeh W,Mouawad JE,Zalzali H,Saab R

    更新日期:2019-01-01 00:00:00

  • Genomic instability is associated with lack of telomerase activation in ovarian cancer.

    abstract:INTRODUCTION:Malignant cells are capable of an unlimited number of cell divisions, either through production of telomerase, or through the alternate lengthening of telomere (ALT) mechanism. Yeast cells with genomic instability have been shown to survive in the absence of telomerase by increased recombination events. We...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.3.12.1235

    authors: Landen CN,Klingelhutz A,Coffin JE,Sorosky JI,Sood AK

    更新日期:2004-12-01 00:00:00

  • Synergistic effect of resveratrol and HSV-TK/GCV therapy on murine hepatoma cells.

    abstract::Despite its low transfer efficiency, suicide gene therapy with HSV-TK is known for its bystander killing effect. The connexin-based gap junction is believed to mediate the bystander effect. Recently, we found that resveratrol, a polyphenol compound, increased the expression of Cx26 and Cx43, which are connexins and im...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2018.1523094

    authors: Xiao J,Wang X,Wu Y,Zhao Q,Liu X,Zhang G,Zhao Z,Ning Y,Wang K,Tan Y,Du B

    更新日期:2019-01-01 00:00:00

  • Stromal-epithelial interactions are responsible for prostate tumor progression through an androgen-related mechanism.

    abstract::While several hypotheses have been put forward to explain how prostate tumors become resistant to androgen deprivation therapy, the mechanism by which prostate tumors have increased androgen concentrations as compared to the serum has been poorly explored. Using a stromal/epithelial cell co-culture model, Mizokami et ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.9.3.11143

    authors: Sharma H,Sissung TM,Pressler H,Figg WD

    更新日期:2010-02-01 00:00:00

  • Binding and inhibition of drug transport proteins by heparin: a potential drug transporter modulator capable of reducing multidrug resistance in human cancer cells.

    abstract::A major problem in cancer treatment is the development of resistance to chemotherapeutic agents, multidrug resistance (MDR), associated with increased activity of transmembrane drug transporter proteins which impair cytotoxic treatment by rapidly removing the drugs from the targeted cells. Previously, it has been show...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.27148

    authors: Chen Y,Scully M,Petralia G,Kakkar A

    更新日期:2014-01-01 00:00:00

  • The role of Rac1 in the regulation of NF-κB activity, cell proliferation, and cell migration in non-small cell lung carcinoma.

    abstract::The small GTPase Rac1 regulates many cellular processes, including cytoskeletal reorganization, cell migration, proliferation, and survival. Additionally, Rac1 plays a major role in activating NF-κB-mediated transcription. Both Rac1 and NF-κB regulate many properties of the malignant phenotype, including anchorage-ind...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.20082

    authors: Gastonguay A,Berg T,Hauser AD,Schuld N,Lorimer E,Williams CL

    更新日期:2012-06-01 00:00:00

  • Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab.

    abstract::The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in human cancers. Cetuximab is an anti-EGFR monoclonal antibody that has been approved for use in oncology. Despite clinical success the majority of patients do not respond to cetuximab and those who initially respond frequently ac...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.24342

    authors: Iida M,Brand TM,Campbell DA,Starr MM,Luthar N,Traynor AM,Wheeler DL

    更新日期:2013-06-01 00:00:00

  • The differences of regulatory networks between papillary and anaplastic thyroid carcinoma: an integrative transcriptomics study.

    abstract:BACKGROUND:Unlike papillary thyroid cancer (PTC), anaplastic thyroid carcinoma (ATC) is extremely aggressive and rapidly lethal without effective therapies. However, the differences of master regulators and regulatory networks between PTC and ATC remain unclear. Methods: Three representative datasets comprising 32 ATC,...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2020.1803009

    authors: Pan Z,Li L,Qian Y,Ge X,Hu X,Zhang Y,Ge M,Huang P

    更新日期:2020-09-01 00:00:00

  • Weighted gene co-expression network analysis and prognostic analysis identifies hub genes and the molecular mechanism related to head and neck squamous cell carcinoma.

    abstract::Head and neck squamous cell carcinoma (HNSCC) is a lethal disease with suboptimal survival outcomes. In this study, we aimed to find an independent prognostic factor of head and neck squamous cell carcinoma and investigate its effect on tumor cell proliferation, apoptosis, migration progress and cell cycle phase. Weig...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2018.1564560

    authors: Li Q,Chen W,Song M,Chen W,Yang Z,Yang A

    更新日期:2019-01-01 00:00:00

  • Apoptotic response to 5-fluorouracil treatment is mediated by reduced polyamines, non-autocrine Fas ligand and induced tumor necrosis factor receptor 2.

    abstract::5-fluorouracil (5-FU) is the major chemotherapeutic agent for treatment of colorectal carcinoma, but the molecular mechanisms of response and resistance are not understood completely. We therefore studied the 5-FU dose response and time course of gene expression transcriptome changes in colon carcinoma cell lines that...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.2.5.532

    authors: Zhang W,Ramdas L,Shen W,Song SW,Hu L,Hamilton SR

    更新日期:2003-09-01 00:00:00

  • NKG2D ligand expression in pediatric brain tumors.

    abstract::Adult brain tumors establish an immunosuppressive tumor microenvironment as a modality of immune escape, with several immunotherapies designed to overcome this barrier. However, the relationship between tumor cells and immune cells in pediatric brain tumor patients is not as well-defined. In this study, we sought to d...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2016.1250047

    authors: Haberthur K,Brennan K,Hoglund V,Balcaitis S,Chinn H,Davis A,Kreuser S,Winter C,Leary SE,Deutsch GH,Ellenbogen RG,Crane CA

    更新日期:2016-12-01 00:00:00

  • Multiplying therapies and reducing toxicity in metastatic melanoma.

    abstract::Prior to 2011, only 2 systemic treatments were approved for the treatment of melanoma and these had limited efficacy. In the past 4 years, 6 novel agents have received FDA approval. Herein, we will focus on 4 recently published NEJM papers reporting the results of clinical trials, comprising 4 agents targeting the MAP...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1046650

    authors: Massey PR,Prasad V,Figg WD,Fojo T

    更新日期:2015-01-01 00:00:00

  • Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy.

    abstract::Numerous tyrosine kinase inhibitors (TKIs) targeting c-Met are currently in clinical trials for several cancers. Their efficacy is limited due to the development of resistance. The present study aims to elucidate this mechanism of c-Met TKI resistance by investigating key mTOR and Wnt signaling proteins in melanoma ce...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.29451

    authors: Etnyre D,Stone AL,Fong JT,Jacobs RJ,Uppada SB,Botting GM,Rajanna S,Moravec DN,Shambannagari MR,Crees Z,Girard J,Bertram C,Puri N

    更新日期:2014-09-01 00:00:00

  • E2F1 as a target: promoter-driven suicide and small molecule modulators.

    abstract::Decreased requirements for mitogens and diminished sensitivity to antiproliferative signals are among the hallmarks of human cancer. These attributes are due, at least partly, to mutations that directly or indirectly compromise the function of the retinoblastoma tumor suppressor protein (pRB), which is a negative regu...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Kaelin WG Jr

    更新日期:2003-07-01 00:00:00

  • Telomerase as a target for cancer immunotherapy.

    abstract::Telomerase is the ribonucleoprotein that enables cancer and stem cells to maintain their telomeres, resulting in unlimited proliferative potential. The catalytic component of telomerase in humans, hTERT, is upregulated in nearly 90% of all cancers, making it the most widely expressed marker of malignancy. With the exc...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.2.2.255

    authors: Nguyen B,Elmore LW,Holt SE

    更新日期:2003-03-01 00:00:00

  • Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients.

    abstract::Bevacizumab, is a humanized monoclonal antibody to vasculo-endothelial-growth-factor, with anticancer activity in non-small-cell-lung cancer (NSCLC) patients. Our previous results from a dose/finding phase I trial in NSCLC patients, demonstrated the anti-angiogenic effects and toxicity of a newest bevacizumab-based co...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.12.2.15722

    authors: Correale P,Botta C,Basile A,Pagliuchi M,Licchetta A,Martellucci I,Bestoso E,Apollinari S,Addeo R,Misso G,Romano O,Abbruzzese A,Lamberti M,Luzzi L,Gotti G,Rotundo MS,Caraglia M,Tagliaferri P

    更新日期:2011-07-15 00:00:00

  • RNA interference of MBD1 in BxPC-3 human pancreatic cancer cells delivered by PLGA-poloxamer nanoparticles.

    abstract::Methyl-CpG binding domain protein 1 (MBD1) is a transcriptional regulator that binds methylated CpG islands of tumor suppressor genes and represses their transcription. In a former study, we found high expression of MBD1 in pancreatic cancer cell lines and tissues which may play an important role in the development of...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.8.7.7790

    authors: Luo G,Jin C,Long J,Fu D,Yang F,Xu J,Yu X,Chen W,Ni Q

    更新日期:2009-04-01 00:00:00

  • DNA ploidy and S phase fraction of breast and ovarian tumor cells treated with a natural anthracycline analog (aloin).

    abstract::DNA ploidy and S phase fraction analysis by flow cytometry on breast and ovarian tumor cells continuously exposed to aloin, a natural anthraquinone, at two concentrations (20-60 microg/ml) was done. Untreated breast and ovarian tumor cells (control) showed an aneuploid pattern, with a mean DNA index of 2.10+/-0.10 and...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.4.1.1445

    authors: Esmat AY,El-Gerzawy SM,Rafaat A

    更新日期:2005-01-01 00:00:00

  • Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.

    abstract::Tumor growth is often associated with insufficient apoptosis. The Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) and its proapoptotic receptors death receptor 4 (DR4) and DR5 agonistic monoclonal antibodies are being developed as targeted therapeutics because they kill cancer cells while sparing...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.12.4.17174

    authors: Zhou L,Wang W,Dicker DT,Humphreys RC,El-Deiry WS

    更新日期:2011-08-15 00:00:00

  • PIK3R3 promotes chemotherapeutic sensitivity of colorectal cancer through PIK3R3/NF-kB/TP pathway.

    abstract::Phosphoinositide-3-kinase regulatory subunit 3(PIK3R3) is overexpressed in different types of human cancer. We previously reported the important role of PIK3R3 in colorectal cancer (CRC). However, the prognosis effect of PIK3R3 in CRC is still remaining unclear. In this study, we explored online clinical databases to ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2017.1416936

    authors: Ibrahim S,Li G,Hu F,Hou Z,Chen Q,Li G,Luo X,Hu J,Feng Y

    更新日期:2018-03-04 00:00:00

  • mRNA expression profile of multidrug-resistant genes in acute lymphoblastic leukemia of children, a prognostic value for ABCA3 and ABCA2.

    abstract::Multidrug resistance (MDR) is an important cause of treatment failure in acute lymphoblastic leukemia (ALL). The ABC family of membrane transporters is proposed, albeit with controversy, to be involved in this process. The present study aims to investigate the mRNA expression profile of several genes of this family, i...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.26603

    authors: Rahgozar S,Moafi A,Abedi M,Entezar-E-Ghaem M,Moshtaghian J,Ghaedi K,Esmaeili A,Montazeri F

    更新日期:2014-01-01 00:00:00